AApoAIV amyloidosis
ORPHA: 4392321 Treatment Available
Overview
human disease
Available Treatments (1)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| Tafamidis Orphan | Oral capsule 20mg, 61mg | FDA Approved | 9 | 10d |
Clinical Presentation
Signs and symptoms associated with AApoAIV amyloidosis, sourced from HPO and Orphanet clinical annotations.
Elevated circulating creatinine concentrationAbnormal renal medulla morphologyHypertensionRenal amyloidosisChronic kidney diseaseAbnormal cardiac ventricular functionRenal interstitial amyloid depositsProteinuriaGlomerular sclerosisDiabetes mellitusHypertrophic cardiomyopathyCoronary artery atherosclerosisLeft ventricular hypertrophyHyperlipidemiaBack painChronic pulmonary obstructionAbnormality of the gastrointestinal tractLeft bundle branch blockReduced left ventricular ejection fractionParaproteinemiaCardiac conduction abnormalityLeft ventricular outflow tract obstructionParoxysmal nocturnal dyspneaSinus bradycardiaAbnormal lung morphologySupravalvular aortic stenosisAtrial flutterAtrial fibrillationCutaneous amyloidosisCardiac amyloidosis
Classification & Codes
Orphanet Code
ORPHA:439232AApoAIV amyloidosis
| Orphanet | ORPHA:439232 |
| Treatments | 1 drug(s) |
| Symptoms on record | 30 signs |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO